個人化醫療：技術及全球市場 是由出版商BCC Research在2009年07月所出版的。
這份英文市場調查報告書包含190 pages 價格從美金4850起跳。
本報告書內容包括：全球個人化醫療（客置化醫療）市場動向之地區・技術類型・產品/服務・應用等各種分類別調查分析、市場規模現況・預測（至2014年）、市場發展因素・阻礙發展因素、主要企業、最近的發展動向等。內容綱要摘記如下：
第1章 介紹
第2章 摘要
第3章 市場概要
- 動向變化
- 主要市場發展因素
- 阻礙發展因素
- 利害關係人的機會
- 總體市場定義
- 技術市場定義
- 產品及服務市場定義
- 應用定義
第4章 全球個人化醫療市場：技術別
- 技術別專利分析
- 個人化醫療的藥物基因組學市場
- 個人化醫療的POC市場
- 個人化醫療的代謝學市場
- 個人化醫療的藥理基因學市場
- 個人化醫療的藥物動態學市場
- 個人化醫療的藥力學市場
第5章 全球個人化醫療市場：服務別
- 新藥開發／給藥技術・服務
- 診斷服務
- 監視／治療服務
- 其他服務
第6章 全球個人化醫療市場：產品別
第7章 全球個人化醫療市場：應用別
- 乳癌
- 白血病
- 肺癌
- HIV／AIDS治療
- 神經疾病
- 氣喘
第8章 全球個人化醫療市場：地區別
第9章 企業介紹
第10章 附錄
Abstract
REPORT HIGHLIGHTS
The global market for personalized medicine technology is projected to be
$14.4 billion in 2009 and is expected to reach $29.2 billion in 2014, for a
compound annual growth rate (CAGR) of 15.2% Pharmacogenomics is a major
revenue generating market, contributing about 28.7% to the total personalized
medicine market in 2009, at $4.1 billion; this should reach $9.5 billion in
2014, for a CAGR of 18% The point-of-care market has the second largest share
of the market, at $2.7 billion in 2009. This is expected to increase to $5.1
billion in 2014, for a CAGR of 18%.
STUDY GOALS AND OBJECTIVES
- To measure the personalized medicine market, which has experienced high
growth year to year.
- To analyze the current personalized medicine business model and to
evaluate the commercial use of the personalized medicine technology platform.
- To analyze individual submarkets for personalized medicine in terms of
technology, products, services, application areas and geography.
- To estimate the growth rate of all the submarkets based on various factors.
- To analyze and forecast the market data for each subsegment for the next 5
years.
- To define and identify the high growth markets among the subsegments of
the personalized medicine market.
- To strategically discuss the trends and market opportunities for the
various stakeholders in identifying the focus areas within the market.
- To strategically analyze the competitive landscape and the participation
of all the top companies in the market.
REASONS FOR DOING THE STUDY
Personalized diagnosis and treatment - or personalized medicine - is the
most recent trend in the multibillion - dollar molecular diagnostics industry.
Pharmaceutical and biotechnology companies are increasingly turning to
personalized medicine in order to improve the drug development process and
also to speed up the approval of new drugs.
According to the industry consensus, personalized medicine will not only form
an integral part of mainstream medicine in the next few years, it is also
expected to reform the development, testing, marketing and prescription of
drugs during the next decade. The big pharmaceutical companies eventually will
change their tried - and - tested blockbuster business model to more -
targeted and effective healthcare solutions.
Several diagnostic and life - science companies have yet to tap the complete
personalized medicine market, which is experiencing rapid growth all over the
world. A detailed study of the different subsegments within personalized
medicine is required for existing and new players to develop new strategies to
harness the expanding market. This research report will address this need by
analyzing market trends, new and available opportunities and the current
competitive landscape in the personalized medicine market.
SCOPE OF REPORT
The personalized medicine market is segmented according to products, services,
technology, applications and geography. Each section will provide market data,
market drivers, trends and opportunities, top - selling products and the
profiles of key market players. Along with the company profiles, the report
will feature market tables to provide complete insight on the market. All
market tables are categorized according to products, services, technologies,
applications and geography. The report also highlights the strategic issues
involved in tapping the personalized medicine market, which is reporting
double - digit growth year - on - year.
INTENDED AUDIENCE
The intended audience includes all the stakeholders (except end - users) of
the personalized medicine market: Equipment manufacturers, specialized
technology providers, pharmaceutical companies, biotechnology companies and
diagnostic companies and physicians.
This report provides all the necessary information for all industry
participants to understand the market scenario and develop marketing
strategies based on the opportunities highlighted here. The market data and
forecasts made up to the year 2014 explain the demand for products and
services.
INFORMATION SOURCES AND METHODOLOGY
The market data will consist of aggregate revenues generated from all
submarkets within the personalized medicine market. We have analyzed existing
and new technologies in the personalized medicine market, and studied the new
products introduced in these categories. The report examines all the
application areas and also identifies the unexplored markets. We have
researched all technology patents over the last 5 years. We have also analyzed
the key market developments of the top companies, and provided profiles for
each of these players. Information has been collected through paid and unpaid
secondary sources; and primary research was conducted to get a more in - depth
understanding of the facts and facets of the industry.
Table of Contents
Chapter-1: SUMMARY 2
- SUMMARY TABLE GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY
TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 4
- SUMMARY FIGURE GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY
TECHNOLOGY, 2007-2014 ($ MILLIONS) 5
Chapter-2: MARKET OVERVIEW 15
- MARKET OVERVIEW 6
- FIGURE 1 PERSONALIZED MEDICINE VS CONVENTIONAL TREATMENTS 7
- FIGURE 2 FOCUS OF PERSONALIZED MEDICINE 8
- CHANGING TRENDS: FROM BLOCKBUSTER MODEL TO PERSONALIZED MODEL 9
- FIGURE 3 PERSONALIZED MEDICINE VS BLOCKBUSTER DRUGS 10
- MAJOR MARKET DRIVERS 11
- ACCURACY AND PREVENTIVE DIAGNOSIS 11
- COST - EFFECTIVE IN LONG RUN 11
- RECUPERATIVE BENEFITS 11
- MORE EFFECTIVE THAN CONVENTIONAL TREATMENTS 11
- MARKET RESTRAINTS 11
- RELUCTANCE AMONG PHARMACEUTICAL COMPANIES 12
- LEGAL ISSUES DUE TO INTELLECTUAL PROPERTY RIGHTS 12
- LACK OF INSURANCE COVERAGE 12
- FIGURE 4 MAJOR MARKET TRENDS IN PERSONALIZED MEDICINE 13
- STAKEHOLDERS' OPPORTUNITIES 13
- FIGURE 5 PARTICIPATION OF STAKEHOLDERS 14
- TABLE 1 GLOBAL MARKET FOR STAKEHOLDERS, THROUGH 2014 ($ MILLIONS) 15
- DEFINING THE OVERALL PERSONALIZED MEDICINE MARKET 15
- FIGURE 6 MARKET STRUCTURE FOR PERSONALIZED MEDICINE 15
- DEFINING THE PERSONALIZED MEDICINE TECHNOLOGY MARKET 16
- FIGURE 7 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY
TECHNOLOGY, 2007-2014 ($ MILLIONS) 16
- DEFINING THE PERSONALIZED MEDICINE PRODUCTS AND SERVICES MARKET 17
- TABLE 2 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS AND SERVICES,
THROUGH 2014 ($ MILLIONS) 17
- DEFINING THE PERSONALIZED MEDICINE APPLICATIONS MARKET 18
- TABLE 3 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATION,
THROUGH 2014 ($ MILLIONS) 18
- DEFINING THE PERSONALIZED MEDICINE MARKET BY GEOGRAPHY 18
- FIGURE 8 GLOBAL MARKETS FOR PERSONALIZED MEDICINE, 2009 (%) 19
- PATENT ANALYSIS 19
- FIGURE 9 NUMBERS OF PATENTS ISSUED, JAN. 2004 - APR. 2009 20
Chapter-3: GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY 40
- GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY 21
- FIGURE 10 POSITIONING VARIOUS TECHNOLOGIES IN THE MARKET FOR PERSONALIZED
MEDICINE 22
- ANALYSIS OF PATENTS BY TECHNOLOGY 23
- FIGURE 11 SHARE OF PATENTS BY TECHNOLOGY (%) 23
- GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE 24
- TABLE 4 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY
PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 24
- TABLE 5 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 25
- MARKET DRIVERS 25
- Increased Health Awareness and Preventive Diagnosis to Boost the Demand
for Pharmacogenomics 25
- Increased Revenue Opportunities for Diagnostic and Drug Companies 25
- Enhanced Treatment and Better Drug Efficacy Rate 25
- MARKET RESTRAINTS 26
- Intellectual Property Rights Problem 26
- Legal Issues within Nations 26
- PHARMACOGENOMIC SERVICES MARKET 26
- TABLE 6 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY
SERVICES, THROUGH 2014 ($ MILLIONS) 27
- TABLE 7 GLOBAL PHARMACOGENOMICS SERVICES MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 27
- Global Market for SNP Genotyping 27
- Cost Effective Sequencing Boosts Demand 28
- Oligopoly Market Restrains Entry of New Companies 28
- Global Market for SNP Genotyping Services 28
- TABLE 8 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY
DIAGNOSIS METHODS, THROUGH 2014 ($ MILLIONS) 29
- TABLE 9 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY SERVICES,
THROUGH 2014 ($ MILLIONS) 29
- Global Market for SNP Genotyping Products 29
- TABLE 10 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY
PRODUCTS, THROUGH 2014 ($ MILLIONS) 30
- Major Companies and Products 30
- TABLE 11 MAJOR PRODUCTS IN SNP GENOTYPING 30
- Global Market for Pharmacogenomic Drug Discovery and Delivery 30
- TABLE 12 GLOBAL DRUG DISCOVERY AND DELIVERY MARKET IN PHARMACOGENOMICS,
THROUGH 2014 ($ MILLIONS) 31
- Market for SSR - Based Diagnosis 31
- TABLE 13 GLOBAL SSR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 32
- Market for VNTRs - Based Diagnosis 32
- TABLE 14 GLOBAL VNTR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 32
- Global Market for Pharmacogenomic Therapy 33
- TABLE 15 GLOBAL PHARMACOGENOMIC THERAPY MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 33
- Global Market for Other Pharmacogenomic Services 33
- TOP COMPANIES 33
- TABLE 16 MAJOR COMPANIES AND RESPECTIVE PRODUCTS IN PHARMACOGENOMIC
SERVICES 34
- PHARMACOGENOMIC PRODUCTS MARKET 34
- TABLE 17 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY
PRODUCTS, THROUGH 2014 ($ MILLIONS) 34
- TABLE 18 GLOBAL PHARMACOGENOMICS PRODUCTS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 35
- Markets for Pharmacogenomic Drugs 35
- TABLE 19 GLOBAL PHARMACOGENOMICS DRUGS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 35
- Markets for Equipment in Pharmacogenomics 36
- TABLE 20 GLOBAL PHARMACOGENOMICS EQUIPMENT MARKET IN PERSONALIZED
MEDICINE, THROUGH 2014 ($ MILLIONS) 36
- MAJOR TECHNIQUES 36
- TABLE 21 GLOBAL MARKET FOR MAJOR PHARMACOGENOMIC TECHNIQUES IN
PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 37
- GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE 37
- TABLE 22 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY
PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 38
- TABLE 23 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 38
- MARKET DRIVERS 38
- Superior Diagnostic Results with Protein Studies 38
- High Revenue Generation Attracts More Market Players 39
- MARKET RESTRAINTS 39
- Continuous Change in Protein Formation Makes it a Costly Treatment 39
- TOP COMPANIES 39
- TABLE 24 MAJOR PRODUCTS IN PHARMACOPROTEOMICS 39
- MARKET FOR PHARMACOPROTEOMICS SERVICES 40
- TABLE 25 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY
SERVICES, THROUGH 2014 ($ MILLIONS) 40
- TABLE 26 GLOBAL PHARAMCOPROTEOMICS SERVICES MARKET IN PERSONALIZED
MEDICINE, THROUGH 2014 ($ MILLIONS) 41
- PHARMACOPROTEOMIC PRODUCTS 41
- TABLE 27 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY
PRODUCTS, THROUGH 2014 ($ MILLIONS) 41
- TABLE 28 GLOBAL PHARAMCOPROTEOMICS PRODUCTS MARKET IN PERSONALIZED
MEDICINE, THROUGH 2014 ($ MILLIONS) 42
- TABLE 29 GLOBAL PHARAMCOPROTEOMICS DRUGS MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 42
- MAJOR TECHNOLOGIES 43
- TABLE 30 GLOBAL PHARAMCOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY
MAJOR TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 43
- GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE 43
- TABLE 31 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE BY
TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 44
- TABLE 32 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 44
- MARKET DRIVERS 45
- Highly Untapped Market 45
- Multiple Treatments with One Stem Cell 45
- Government Appreciation in the U.S. for Embryonic Stem Cell Research 45
- MARKET RESTRAINTS 45
- Time Consuming Treatment 45
- Side Effects 46
- TOP COMPANIES 46
- TABLE 33 MAIN COMPANIES AND PRODUCTS IN STEM CELL THERAPY 46
- TABLE 34 RECENT PRODUCTS IN STEM CELL THERAPY 46
- ADULT STEM CELL THERAPY 47
- TABLE 35 GLOBAL ADULT STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 47
- Market Drivers 47
- Enhanced Treatment for Spinal Cord Injury and Diseases such as Cancer 47
- Federal Funding in the U.S. for Adult Stem Cell Therapy 48
- Market Restraints 48
- Stem Cell Therapy Requires Frequent Treatment 48
- EMBRYONIC STEM CELL THERAPY 48
- Market Drivers 49
- Enhanced Curative Potential Will Attract More Customers 49
- Sufficient Knowledge on many Ranges of Stem Cells 49
- Market Restraints 49
- Religious and Political Issues 49
- OTHER TECHNIQUES 49
- GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE 50
- TABLE 36 GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 50
- MARKET DRIVERS 51
- Fast, Easy, and Exact Personalized Care 51
- Developed Technology Paves the Way for a Developed Market 51
- MARKET RESTRAINTS 51
- Time - Consuming Realization of Insurance Policies 51
- TOP COMPANIES AND THEIR PRODUCTS 51
- TABLE 37 TOP COMPANIES AND THEIR PRODUCTS IN POINT OF CARE 51
- TABLE 37 (CONTINUED) 52
- TABLE 38 NEW TECHNOLOGIES IN POINT OF CARE 52
- GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE 52
- TABLE 39 GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014
($ MILLIONS) 53
- MARKET DRIVERS 53
- Enhanced R&D in Drug Discovery Process 53
- Competitive Advantage and Less Regulatory Hurdles in Final Drug Delivery 53
- MARKET RESTRAINTS 54
- Adopted by Fewer Companies 54
- TOP COMPANIES 54
- TABLE 40 MAJOR COMPANIES AND THEIR PRODUCTS 54
- GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE 54
- TABLE 41 GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 55
- MARKET DRIVERS 55
- Preventive and Curative Treatments Use Pharmacogenetic Technique 55
- Enhanced Drugs for Diseases such as Cancer/Cardiovascular Problems 55
- MARKET RESTRAINTS 56
- High Cost 56
- TOP COMPANIES 56
- TABLE 42 MAIN PRODUCTS IN PHARMACOGENETICS 56
- GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE 56
- TABLE 43 GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 57
- MARKET DRIVERS 57
- Better Evaluation of the Body' s Response to the Drug 57
- Quantitative Results Make it User Friendly for Patients 57
- Untapped Market Means Potential Growth for Companies 58
- MARKET RESTRAINTS 58
- Assumptions of Mathematical Models Can Give Unwanted Results 58
- Costly Treatment Hampers Market Growth 58
- TOP COMPANIES 58
- TABLE 44 MAIN PRODUCTS IN PHARMACOKINETICS 59
- GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE 59
- TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS)
- TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) (contd) 59
Chapter-4: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY SERVICES 10
- TABLE 46 GLOBAL PERSONALIZED MEDICINE MARKET BY SERVICES, THROUGH 2014 ($
MILLIONS) 61
- TABLE 47 GLOBAL PERSONALIZED MEDICINE SERVICES MARKET, THROUGH 2014 ($
MILLIONS) 62
- GLOBAL MARKET FOR DRUG DEVELOPMENT/DRUG DELIVERY SERVICE 62
- TABLE 48 GLOBAL DRUG DEVELOPMENT AND DELIVERY MARKET IN PERSONALIZED
MEDICINE, THROUGH 2014 ($ MILLIONS) 62
- MARKET DRIVERS 63
- Shift of Trend from Blockbuster Drugs to Tailored Drugs 63
- Higher Efficacy of Drugs with Personalized Medicine 63
- MARKET RESTRAINTS 63
- Expensive Drugs In Comparison To Blockbuster Drugs 63
- TOP COMPANIES 63
- GLOBAL MARKET FOR DIAGNOSIS 63
- TABLE 49 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, BY
TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 64
- TABLE 50 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, THROUGH
2014 ($ MILLIONS) 65
- PHARMACOGENOMICS BASED DIAGNOSIS 65
- TABLE 51 GLOBAL PHARMACOGENOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014
($ MILLIONS) 66
- Market Drivers 66
- Individual Gene Tests are Increasing Revenues for Diagnostic Players 66
- Market Restraints 66
- Rapidly Evolving Technology is Not Aligned to Fixed Regulatory System 66
- PHARMACOPROTEOMICS BASED DIAGNOSIS 66
- TABLE 52 GLOBAL PHARMACOPROTEOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014
($ MILLIONS) 67
- Market Drivers 67
- In - Depth Research Provides a Lot of Information for Diagnosis 67
- Market Restraints 67
- Costly Treatment Due to Requirement of Continuous Monitoring of Changing
Protein Formation 67
- PHARMACOGENETICS BASED DIAGNOSIS 68
- TABLE 53 GLOBAL PHARMACOGENETIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014
($ MILLIONS) 68
- GLOBAL MARKET FOR MONITORING AND THERAPY SERVICES 68
- MONITORING SERVICES 68
- TABLE 54 GLOBAL PERSONALIZED MEDICINE MONITORING SERVICES MARKET, THROUGH
2014 ($ MILLIONS) 69
- THERAPEAUTIC SERVICES 69
- TABLE 55 GLOBAL PERSONALIZED MEDICINE THERAPEUTIC SERVICES MARKET, THROUGH
2014 ($ MILLIONS) 69
- GLOBAL MARKET FOR OTHER SERVICES 69
- TABLE 56 GLOBAL OTHER SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH
2014 ($ MILLIONS) 70
Chapter-5: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS 15
- TABLE 57 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS, THROUGH 2014 ($
MILLIONS) 71
- TABLE 58 GLOBAL PERSONALIZED MEDICINE PRODUCTS MARKET, THROUGH 2014 ($
MILLIONS) 72
- GLOBAL PERSONALIZED MEDICINE MARKET FOR DIAGNOSTICS EQUIPMENT 72
- TABLE 59 GLOBAL MARKET FOR DIAGNOSTIC EQUIPMENT IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 72
- MARKET DRIVERS 73
- Increased Demand for Genetic and Proteomic Tests 73
- MARKET RESTRAINTS 73
- Fast Changing Technology 73
- TABLE 60 GLOBAL MARKET FOR MONITORING AND THERAPEUTIC EQUIPMENT IN
PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS) 73
- MARKET DRIVERS 74
- Improved Technology Along with Low - Cost Monitoring and Therapeutic
Devices 74
- GLOBAL PERSONALIZED MEDICINE MARKET FOR BIOINFORMATICS PRODUCTS 74
- TABLE 61 GLOBAL MARKET FOR BIOINFORMATICS IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 74
- MARKET DRIVERS 75
- Bioinformatics Reduces Cost of Drug Development 75
- MARKET RESTRAINTS 75
- High Initial Investment Hinders Small and Medium Sized Companies 75
- GLOBAL PERSONALIZED MEDICINE MARKET FOR DRUGS 75
- TABLE 62 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE BY
PRODUCTS, THROUGH 2014 ($ MILLIONS) 76
- TABLE 63 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 76
- DRUG STAGES 76
- FIGURE 12 PRODUCT LIFE CYCLE FOR PERSONALIZED MEDICINE PRODUCTS 77
- GLEEVEC 78
- TABLE 64 GLOBAL MARKET FORECAST FOR GLEEVAC IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 78
- Market Drivers 78
- Higher Efficacy of Gleevec Gives it a Large Consumer Base 78
- Gleevec as a Pill Makes it Easy to Consume 79
- Assistance for Reimbursement from Insurance Companies 79
- Market Restraints 79
- High Drug Cost is Affecting Market Growth 79
- Inherent Side Effects of Gleevec 79
- HERCEPTIN 79
- TABLE 65 GLOBAL MARKET FORECAST FOR HERCEPTIN IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 80
- Market Drivers 80
- Enhanced Treatment with Reduced Risk of Reoccurrence of Breast Cancer 80
- Market Restraints 80
- Tailor Made Herceptin Still Carries Inherent Side Effects 80
- ZIAGEN 81
- TABLE 66 GLOBAL MARKET FORECAST FOR ZIAGEN IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 81
- Market Drivers 81
- Customizable for Children 81
- Market Restraints 82
- Treatment with Ziagen Cannot Be Restarted 82
- IRESSA AND TARCEVA 82
- Iressa 82
- Market Drivers 82
- " Iressa in Pills Makes it User Friendly 82
- Market Restraints 83
- " FDA Ban on Iressa Is Keeping it Away from the U.S. Market 83
- Tarceva 83
- TABLE 67 GLOBAL MARKET FORECAST FOR IRESSA & TARCEVA IN PERSONALIZED
MEDICINE, THROUGH 2014 ($ MILLIONS) 83
- ERBITUX 84
- TABLE 68 GLOBOL MARKET FORECAST FOR ERBITUX IN PERSONALIZED MEDICINE
THROUGH 2014 ($ MILLIONS) 84
- Market Drivers 85
- Multiple Cancers Are Treated with Erbitux, which Gives it a Large Patient
Base 85
- Enhanced Survival Results when Radiotherapy Is Combined with Erbitux 85
- OTHERS 85
- TABLE 69 GLOBAL MARKET FORECAST FOR OTHER DRUGS IN PERSONALIZED MEDICINE,
THROUGH 2014 ($ MILLIONS) 85
Chapter-6: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS 16
- GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS 86
- FIGURE 13 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY
APPLICATION, THROUGH 2014 ($ BILLIONS) 87
- PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR DISEASE 87
- TABLE 70 GLOBAL MARKET FORECAST FOR TREATMENT OF CARDIOVASCULAR DISEASES,
THROUGH 2014 ($ MILLIONS) 88
- MARKET DRIVERS 88
- Possible Preventive Measure 88
- MARKET RESTRAINTS 89
- Lack of Proactive Approach for Early Diagnosis 89
- PERSONALIZED MEDICINE MARKET FOR BREAST CANCER 89
- TABLE 71 GLOBAL MARKET FORECAST FOR BREAST CANCER TREATMENT THROUGH 2014
($ MILLIONS) 90
- MARKET DRIVERS 90
- Fewer Side Effects with Personalized Medicine 90
- MARKET RESTRAINTS 90
- Resistance to Adopting New Methods of Treatment 90
- RECENT DEVELOPMENTS 90
- TABLE 72 RECENT DEVELOPMENTS IN TREATMENT OF BREAST CANCER 91
- PERSONALIZED MEDICINE MARKET FOR LEUKEMIA 91
- TABLE 73 GLOBAL MARKET FORECAST FOR LEUKEMIA TRETAMENT THROUGH 2014 ($
MILLIONS) 92
- MARKET DRIVERS 92
- Huge Market Potential for Leukemia 92
- MARKET RESTRAINTS 92
- Lack of Awareness that Surgery Is the Only Way to Treat Leukemia 92
- PERSONALIZED MEDICINE MARKET FOR LUNG CANCER 92
- TABLE 74 GLOBAL MARKET FORECAST FOR LUNG CANCER TREATMENT, THROUGH 2014 ($
MILLIONS) 93
- MARKET DRIVERS 93
- Higher Efficiency Than Conventional Lung Cancer Treatment 93
- Availability of Drugs in the Form of Pills Makes Treatment User Friendly 93
- MARKET RESTRAINTS 94
- Lack of FDA Approval for Certain Personalized Drugs 94
- RECENT DEVELOPMENTS 94
- PERSONALIZED MEDICINE MARKET FOR TREATING HIV/AIDS 94
- TABLE 75 GLOBAL MARKET FORECAST FOR AIDS TREATMENT THROUGH 2014 ($
MILLIONS) 95
- MARKET DRIVERS 95
- Personalized Medicine Improves Life Expectancy of a Patient 95
- Easy Reimbursement for Aids Patients from NGOs/Government Organizations 95
- MARKET RESTRAINTS 95
- Lack of Awareness Among Patients 95
- PERSONALIZED MEDICINE MARKET FOR NEUROLOGICAL DISORDERS 96
- TABLE 76 GLOBAL MARKET FORECAST FOR TREATING NEUROLOGICAL DISORDERS,
THROUGH 2014 ($ MILLIONS) 96
- MARKET DRIVERS 96
- Enhanced Treatment 96
- MARKET RESTRAINTS 97
- Apprehensive to Try Out New Medications 97
- PERSONALIZED MEDICINE MARKET FOR DIABETES 97
- TABLE 77 GLOBAL MARKET FORECAST FOR TREATMENT OF DIABETES, THROUGH 2014 ($
MILLIONS) 97
- MARKET DRIVERS 98
- Early Diagnosis Can Help Prevent Diabetes 98
- MARKET RESTRAINTS 98
- Casual Approach towards Diabetes 98
- RECENT DEVELOPMENTS 98
- TABLE 78 RECENT DEVELOPMENTS IN TREATING DIABETES 98
- PERSONALIZED MEDICINE MARKET FOR ASTHMA 99
- TABLE 79 GLOBAL MARKET FORECAST FOR TREATING ASTHMA, THROUGH 2014 ($
MILLIONS) 99
- MARKET DRIVERS 99
- Every Asthma Case Is Distinct, Needs Custom - Tailored Treatment 99
- Asthma Treatment Needs Regular Monitoring 100
- OTHER APPLICATIONS 100
- TABLE 80 GLOBAL MARKET FORECAST FOR TREATING OTHER CANCER/TUMOR, THROUGH
2014 ($ MILLIONS) 100
- TABLE 81 GLOBAL MARKET FORECAST FOR TREATING OTHER DISEASES, THROUGH 2014
($ MILLIONS) 101
Chapter-7: GLOBAL PERSONALIZED MARKET BY GEOGRAPHY 16
- ABBOTT 118
- OVERVIEW 118
- TABLE 97 PRODUCT PORTFOLIO OF ABBOTT 118
- TABLE 97 (CONTINUED) 119
- STRATEGY 119
- AFFYMETRIX 120
- OVERVIEW 120
- TABLE 98 PRODUCT PORTFOLIO OF AFFYMETRIX (MICROARRAYS) 120
- TABLE 98 (CONTINUED) 121
- TABLE 98 (CONTINUED) 122
- TABLE 99 PRODUCT PORTFOLIO OF AFFYMETRIX (REAGENTS & ASSAYS) 122
- TABLE 99 (CONTINUED) 123
- STRATEGY 123
- AGENDIA BV 123
- OVERVIEW 124
- TABLE 100 PRODUCT PORTFOLIO OF AGENDIA BV 124
- STRATEGY 124
- ASURAGEN 124
- OVERVIEW 124
- TABLE 101 PRODUCT PORTFOLIO OF ASURAGEN 125
- STRATEGY 125
- BAYER HEALTHCARE 126
- TABLE 102 PRODUCT PORTFOLIO OF BAYER HEALTHCARE 126
- STRATEGY 126
- BIOGEN (IDEC) 127
- OVERVIEW 127
- TABLE 103 PRODUCT PORTFOLIO OF BIOGEN (IDEC) 127
- STRATEGY 127
- BRISTOL - MYERS SQUIBB 128
- OVERVIEW 128
- TABLE 104 PRODUCT PORTFOLIO OF BRISTOL - MYERS SQUIBB 128
- STRATEGY 128
- CELERA DIAGNOSTICS 129
- OVERVIEW 129
- TABLE 105 PRODUCT PORTFOLIO OF CELERA DIAGNOSTICS 129
- TABLE 106 NEW PRODUCT DEVELOPMENT OF CELERA DIAGNOSTICS 130
- STRATEGY 130
- CEPHEID 130
- OVERVIEW 130
- TABLE 107 PRODUCT PORTFOLIO OF CEPHEID 131
- TABLE 107 (CONTINUED) 132
- TABLE 107 (CONTINUED) 133
- STRATEGY 133
- CLINICAL DATA 133
- OVERVIEW 134
- TABLE 108 PRODUCT PORTFOLIO OF CLINICAL DATA 134
- TABLE 108 (CONTINUED) 135
- STRATEGY 135
- CURAGEN CORP. 135
- OVERVIEW 136
- TABLE 109 PRODUCT PORTFOLIO OF CURAGEN CORP. 136
- STRATEGY 136
- DAKO DENMARK A/S 136
- OVERVIEW 137
- TABLE 110 PRODUCT PORTFOLIO OF DAKO DENMARK A/S 137
- TABLE 110 (CONTINUED) 138
- STRATEGY 138
- DECODE GENETICS 138
- OVERVIEW 138
- TABLE 111 PRODUCT PORTFOLIO OF DECODE GENETICS 139
- TABLE 112 NEW PRODUCT DEVELOPMENT OF DECODE GENETICS 140
- STRATEGY 140
- DNA DIRECT, INC. 141
- OVERVIEW 141
- TABLE 113 PRODUCT PORTFOLIO OF DNA DIRECT, INC 141
- STRATEGY 142
- DXS LTD. 142
- OVERVIEW 142
- TABLE 114 PRODUCT PORTFOLIO OF DXS LIMITED 143
- STRATEGY 143
- EXACT SCIENCES CORP. 144
- OVERVIEW 144
- TABLE 115 PRODUCT PORTFOLIO OF EXACT SCIENCES CORP. 144
- STRATEGY 145
- EXAGEN DIAGNOSTICS 145
- OVERVIEW 145
- TABLE 116 PRODUCT PORTFOLIO OF EXAGEN DIAGNOSTICS 145
- GENE LOGIC (AN OCIMUM BIOSOLUTIONS COMPANY) 146
- OVERVIEW 146
- TABLE 117 PRODUCT PORTFOLIO OF GENE LOGIC 146
- TABLE 117 (CONTINUED) 147
- STRATEGY 148
- GENELEX CORP 148
- OVERVIEW 148
- TABLE 118 PRODUCT PORTFOLIO OF GENELEX CORP 148
- TABLE 118 (CONTINUED) 149
- TABLE 118 (CONTINUED) 150
- STRATEGY 150
- GENENTECH, INC. 150
- OVERVIEW 151
- TABLE 119 PRODUCT PORTFOLIO OF GENENTECH, INC. 151
- TABLE 119 (CONTINUED) 152
- STRATEGY 152
- GENOMIC HEALTH, INC. 152
- OVERVIEW 152
- TABLE 120 PRODUCT PORTFOLIO OF GENOMIC HEALTH INC 153
- STRATEGY 153
- GEN - PROBE 153
- OVERVIEW 153
- TABLE 121 PRODUCT PORTFOLIO OF GEN - PROBE 154
- TABLE 121 (CONTINUED) 155
- TABLE 121 (CONTINUED) 156
- TABLE 122 NEW PRODUCT DEVELOPMENT OF GEN - PROBE 157
- STRATEGY 157
- GENTA 157
- OVERVIEW 157
- TABLE 123 PRODUCT PORTFOLIO OF GENTA 158
- TABLE 124 NEW PRODUCT DEVELOPMENT OF GENTA 158
- STRATEGY 158
- GLAXOSMITHKLINE 159
- OVERVIEW 159
- TABLE 125 PRODUCT PORTFOLIO OF GLAXOSMITHKLINE 159
- STRATEGY 159
- ILLUMINA 160
- OVERVIEW 160
- TABLE 126 PRODUCT PORTFOLIO OF ILLUMINA 160
- TABLE 126 (CONTINUED) 161
- STRATEGY 161
- LUMINEX CORP. 161
- OVERVIEW 162
- TABLE 127 PRODUCT PORTFOLIO OF LUMINEX CORP. 162
- MILLENNIUM 162
- OVERVIEW 163
- TABLE 128 PRODUCT PORTFOLIO OF MILLENNIUM 163
- STRATEGY 163
- MONOGRAM BIOSCIENCES 163
- OVERVIEW 163
- TABLE 129 PRODUCT PORTFOLIO OF MONOGRAM BIOSCIENCES 164
- STRATEGY 165
- MYRIAD GENETICS, INC. 165
- OVERVIEW 165
- TABLE 130 PRODUCT PORTFOLIOS OF MYRIAD GENETICS 165
- TABLE 130 (CONTINUED) 166
- TABLE 130 (CONTINUED) 167
- TABLE 131 NEW PRODUCT DEVELOPMENT OF MYRIAD GENETICS 167
- STRATEGY 167
- NANOGEN 168
- OVERVIEW 168
- TABLE 132 PRODUCT PORTFOLIO OF NANOGEN 168
- TABLE 132 (CONTINUED) 169
- STRATEGY 169
- NOVARTIS 169
- OVERVIEW 170
- TABLE 133 PRODUCT PORTFOLIO OF NOVARTIS 170
- STRATEGY 170
- OSMETECH PLC 171
- OVERVIEW 171
- TABLE 134 PRODUCT PORTFOLIO OF WYETH 171
- STRATEGY 171
- PROMEGA 172
- OVERVIEW 172
- TABLE 135 PRODUCT PORTFOLIO OF PROMEGA 172
- TABLE 135 (CONTINUED) 173
- TABLE 135 (CONTINUED) 174
- STRATEGY 175
- QIAGEN 175
- OVERVIEW 175
- TABLE 136 PRODUCT PORTFOLIO OF QIAGEN 176
- TABLE 136 (CONTINUED) 177
- STRATEGY 177
- ROCHE DIAGNOSTICS 178
- OVERVIEW 178
- TABLE 137 PRODUCT PORTFOLIO OF ROCHE DIAGNOSTICS 178
- TABLE 137 (CONTINUED) 179
- STRATEGY 180
- SIEMENS HEALTHCARE DIAGNOSTICS 180
- OVERVIEW 180
- TABLE 138 PRODUCT PORTFOLIO OF SIEMENS HEALTHCARE DIAGNOSTICS 180
- TABLE 138 (CONTINUED) 181
- STRATEGY 181
- TARGET DISCOVERY, INC. 181
- OVERVIEW 181
- TABLE 139 PRODUCT PORTFOLIO OF TARGET DISCOVERY 182
- STRATEGY 182
- VENTANA MEDICAL SYSTEMS, INC. 182
- OVERVIEW 182
- TABLE 140 PRODUCT PORTFOLIO OF VENTANA MEDICALSYSTEMS, INC. 183
- STRATEGY 183
- WYETH 184
- OVERVIEW 184
- TABLE 141 PRODUCT PORTFOLIO OF WYETH 184
- STRATEGY 184
- APPENDIX 185
- PATENTS ISSUED IN U.S. 185
- TABLE 142 PATENTS ISSUED IN THE UNITED STATES 185
- TABLE 142 (CONTINUED) 186
- TABLE 142 (CONTINUED) 187
- TABLE 142 (CONTINUED) 188
- TABLE 142 (CONTINUED) 189
- TABLE 142 (CONTINUED) 190
- TABLE 142 (CONTINUED) 191
- PATENTS ISSUED IN EUROPE 192
- TABLE 143 PATENTS ISSUED IN EUROPE 192
- PATENTS ISSUED IN JAPAN 193
- TABLE 144 PATENTS ISSUED IN JAPAN 193
|
